Zevra Therapeutics Inc (NASDAQ: ZVRA)’s stock price has surge by 15.71%relation to previous closing price of $9.74. Nevertheless, the company has seen a 25.22% surge in its stock price over the last five trading sessions. zacks.com reported 2025-07-03 that Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
Is It Worth Investing in Zevra Therapeutics Inc (NASDAQ: ZVRA) Right Now?
ZVRA has 36-month beta value of 1.85. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy”, 3 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for ZVRA is 54.03M, and currently, short sellers hold a 8.72% ratio of that float. The average trading volume of ZVRA on July 08, 2025 was 595.29K shares.
ZVRA’s Market Performance
The stock of Zevra Therapeutics Inc (ZVRA) has seen a 25.22% increase in the past week, with a 25.92% rise in the past month, and a 51.68% gain in the past quarter. The volatility ratio for the week is 7.98%, and the volatility levels for the past 30 days are at 4.68% for ZVRA. The simple moving average for the last 20 days is 21.45% for ZVRA stock, with a simple moving average of 37.31% for the last 200 days.
Analysts’ Opinion of ZVRA
Many brokerage firms have already submitted their reports for ZVRA stocks, with H.C. Wainwright repeating the rating for ZVRA by listing it as a “Buy”. The predicted price for ZVRA in the upcoming period, according to H.C. Wainwright is $26 based on the research report published on July 02, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ZVRA reach a price target of $25. The rating they have provided for ZVRA stocks is “Overweight” according to the report published on January 08th, 2025.
Maxim Group gave a rating of “Buy” to ZVRA, setting the target price at $25 in the report published on September 24th of the previous year.
ZVRA Trading at 31.19% from the 50-Day Moving Average
After a stumble in the market that brought ZVRA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 12.36% of gains for the given period.
Volatility was left at 4.68%, however, over the last 30 days, the volatility rate increased by 7.98%, as shares surge +27.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +55.45% upper at present.
During the last 5 trading sessions, ZVRA rose by +25.22%, which changed the moving average for the period of 200-days by +44.86% in comparison to the 20-day moving average, which settled at $9.28. In addition, Zevra Therapeutics Inc saw 149.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZVRA starting from Thompson Rahsaan, who sold 24,000 shares at the price of $9.21 back on Jun 26 ’25. After this action, Thompson Rahsaan now owns 42,666 shares of Zevra Therapeutics Inc, valued at $221,004 using the latest closing price.
RAHSAAN THOMPSON, the Officer of Zevra Therapeutics Inc, proposed sale 24,000 shares at $9.33 during a trade that took place back on Jun 26 ’25, which means that RAHSAAN THOMPSON is holding N/A shares at $223,920 based on the most recent closing price.
Stock Fundamentals for ZVRA
Current profitability levels for the company are sitting at:
- -1.77% for the present operating margin
- 0.79% for the gross margin
The net margin for Zevra Therapeutics Inc stands at -2.27%. The total capital return value is set at -0.49%. Equity return is now at value -204.78%, with -56.78% for asset returns.
Based on Zevra Therapeutics Inc (ZVRA), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at 1.51. The interest coverage ratio of the stock is -19.98.
Currently, EBITDA for the company is -76.4 million with net debt to EBITDA at -0.36. When we switch over and look at the enterprise to sales, we see a ratio of 15.79. The receivables turnover for the company is 3.22for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.02.
Conclusion
To put it simply, Zevra Therapeutics Inc (ZVRA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
